Ruby Prosser Scully

1 week ago | medicalrepublic.com.au | Ruby Prosser Scully

Survivors may have lasting changes to their stress, immunological and cardiovascular functioning. Terrorism may have lasting effects on biological stress, according to research on survivors of the 1995 Oklahoma City bombing. The research found that even if the participants had otherwise healthy lives, there were physiological traces of the event up to seven years later.

1 week ago | medicalrepublic.com.au | Laura Andronicos |Ruby Prosser Scully

And antidepressant withdrawal may be harder after longer use, while depression and loneliness predicts future pain. GLP1-RA drugs don’t seem to trigger adverse psychiatric events and instead appear to improve both physical and emotional wellbeing, a UK systematic review and meta-analysis found.

2 weeks ago | medicalrepublic.com.au | Ruby Prosser Scully

Patient preference may be the most important thing when it comes to timing their intake, promising safety and efficacy data suggests. Patients who take their blood pressure medication at night have no greater health risks than those who take it in the morning, according to new Canadian research. The findings suggest patient preference can play more of a role in when the medicines are taken, overturning the conventional morning approach.

2 weeks ago | oncologyrepublic.com.au | Ruby Prosser Scully

Ivonescimab monotherapy hinted at better progression-free survival than its rival and has been approved by China’s regulator. Ivonescimab monotherapy improves progression-free survival in patients with PD-L1–expressing advanced non-small cell lung cancer (aNSCLC) compared with pembrolizumab, new Chinese research suggests.

2 weeks ago | oncologyrepublic.com.au | Ruby Prosser Scully

Adults with unresectable or metastatic liver cancer now have access to the combination for first-line therapy. US adults now have access to nivolumab with ipilimumab for the first-line treatment of unresectable hepatocellular carcinoma, thanks to new FDA approval. The regulator announced the move on 11 April, citing efficacy and safety data from the CHECKMATE-9DW trial of almost 700 adults with unresectable or metastatic HCC.